These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35149201)

  • 1. Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
    Wang XL; Feng ST; Chen B; Hu D; Wang ZZ; Zhang Y
    Neurosci Lett; 2022 Mar; 774():136515. PubMed ID: 35149201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
    Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
    J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
    Hauser RA; Hubble JP; Truong DD;
    Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
    Chen W; Wang H; Wei H; Gu S; Wei H
    J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
    Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
    BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of istradefylline for Parkinson's disease: A meta-analysis.
    Sako W; Murakami N; Motohama K; Izumi Y; Kaji R
    Sci Rep; 2017 Dec; 7(1):18018. PubMed ID: 29269791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
    Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
    Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
    Tao Y; Liang G
    Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST).
    Shimo Y; Maeda T; Chiu SW; Yamaguchi T; Kashihara K; Tsuboi Y; Nomoto M; Hattori N; Watanabe H; Saiki H;
    Parkinsonism Relat Disord; 2021 Oct; 91():115-120. PubMed ID: 34583302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan.
    Takahashi M; Shimokawa T; Koh J; Takeshima T; Yamashita H; Kajimoto Y; Mori A; Ito H
    J Neurol Sci; 2022 Jan; 432():120078. PubMed ID: 34923334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease.
    Yabe I; Kitagawa M; Takahashi I; Matsushima M; Sasaki H
    Clin Neuropharmacol; 2017; 40(6):261-263. PubMed ID: 28976411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of istradefylline in the Parkinson's disease armamentarium.
    Müller T
    Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
    Paton DM
    Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
    Mizuno Y; Kondo T;
    Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan.
    Takahashi M; Fujita M; Asai N; Saki M; Mori A
    Expert Opin Pharmacother; 2018 Oct; 19(15):1635-1642. PubMed ID: 30281377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Istradefylline - a first generation adenosine A
    Jenner P; Mori A; Aradi SD; Hauser RA
    Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: A single-arm, open-label, prospective, multicenter study.
    Iijima M; Orimo S; Terashi H; Suzuki M; Hayashi A; Shimura H; Mitoma H; Kitagawa K; Okuma Y
    Expert Opin Pharmacother; 2019 Aug; 20(11):1405-1411. PubMed ID: 31039621
    [No Abstract]   [Full Text] [Related]  

  • 20. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
    Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
    Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.